Meeting News

Various tranexamic acid dosing regimens may reduce blood loss in revision TKA

Yale Fillingham
Yale A. Fillingham

DALLAS — Results presented at the American Association of Hip and Knee Surgeons Annual Meeting showed all dosing regimens of tranexamic acid were linked to reduced blood loss in revision total knee arthroplasty.

Yale A. Fillingham, MD, and colleagues randomly assigned 188 patients undergoing revision TKA to receive 1 g pre-incision IV tranexamic acid, 1 g pre- and post-incision IV tranexamic acid, 1 g pre-incision IV and 1-g intraoperative topical tranexamic acid or three doses of 1950 mg oral tranexamic acid given 2 hours preoperatively, 6 hours postoperatively and the morning of postoperative day 1. Reduction in hemoglobin was considered the primary outcome measure.

“Our results demonstrated that all treatments were equivalent in terms of reduction of hemoglobin with ranges of 2.6 g/dL to 2.9 g/dL, on average,” Fillingham said in his presentation here.

He added there were no statistical differences with regard to calculated blood loss, transfusion rates or length of stay between the groups.

“Surgeons should consider using the lowest effective dose, as well as the most cost-effective dosing regimen when they are deciding what to use in the revision knee,” Fillingham said. – by Casey Tingle

 

Reference:

Fillingham YA, et al. Paper 33. Presented at: American Association of Hip and Knee Surgeons Annual Meeting; Nov. 1-4, 2018; Dallas.

 

Disclosure: Fillingham reports no relevant financial disclosures.

Yale Fillingham
Yale A. Fillingham

DALLAS — Results presented at the American Association of Hip and Knee Surgeons Annual Meeting showed all dosing regimens of tranexamic acid were linked to reduced blood loss in revision total knee arthroplasty.

Yale A. Fillingham, MD, and colleagues randomly assigned 188 patients undergoing revision TKA to receive 1 g pre-incision IV tranexamic acid, 1 g pre- and post-incision IV tranexamic acid, 1 g pre-incision IV and 1-g intraoperative topical tranexamic acid or three doses of 1950 mg oral tranexamic acid given 2 hours preoperatively, 6 hours postoperatively and the morning of postoperative day 1. Reduction in hemoglobin was considered the primary outcome measure.

“Our results demonstrated that all treatments were equivalent in terms of reduction of hemoglobin with ranges of 2.6 g/dL to 2.9 g/dL, on average,” Fillingham said in his presentation here.

He added there were no statistical differences with regard to calculated blood loss, transfusion rates or length of stay between the groups.

“Surgeons should consider using the lowest effective dose, as well as the most cost-effective dosing regimen when they are deciding what to use in the revision knee,” Fillingham said. – by Casey Tingle

 

Reference:

Fillingham YA, et al. Paper 33. Presented at: American Association of Hip and Knee Surgeons Annual Meeting; Nov. 1-4, 2018; Dallas.

 

Disclosure: Fillingham reports no relevant financial disclosures.

    See more from American Association of Hip and Knee Surgeons Annual Meeting